search
Back to results

Red Raspberry Polyphenols on Gut Microbiome (RRB2)

Primary Purpose

Healthy Subjects, Pre-diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Raspberry and fructooligosaccharide
Raspberry
Sponsored by
Clinical Nutrition Research Center, Illinois Institute of Technology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Healthy Subjects focused on measuring Pre-diabetes, red raspberry, fructooligosaccharide, metagenomics, polyphenol bioavailability, glycemic response, insulin response

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Non-smoking1 man or woman, 20-60 years of age, inclusive
  2. Group 1 must have a fasting blood glucose between 100-125 mg/dL and inulin ≥ 8 μIU/mL
  3. Group 2 will have a fasting blood glucose below 100 mg/dL and the homeostasis model assessment method of insulin resistance (HOMA-IR) [glucose (μmol/L) × insulin (μunits/μL)/22.5] value less than 1
  4. Judged to be in good health on the basis of the medical history
  5. Able to provide informed consent and comply with study procedures
  6. Able to comply to the study instructions (including dietary restrictions, consumption of study beverage, records of food diary and GI-tract questionnaire, sample collection procedure and study visit schedule)
  7. Able to maintain your usual physical activity pattern
  8. Able to abstain from alcohol consumption and avoid vigorous physical activity for 24 hours prior to and during study visit

Exclusion Criteria:

  1. Systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg at screening visit.
  2. Major trauma or a surgical event within 2 months or longer depending on trauma or event and after consultation with PI.
  3. Weight change ≥4.5 kg (9.9 lbs) within 2 months
  4. Presence of chronic constipation, diarrhea or other chronic gastrointestinal complaint (e.g. irritable bowel syndrome)
  5. Had gastrointestinal barium opaque meal within 3 months
  6. History or presence of clinically important endocrine, cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, or biliary that, in the opinion of the investigator, could interfere with the interpretation of the study results
  7. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer
  8. History of extreme dietary habits, as judged by the investigator (e.g., Atkins diet, etc.)
  9. History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional
  10. Vegan or other extreme dietary regimens as judged by the investigator.
  11. Has a known intolerance or sensitivity to any ingredients in the study products
  12. Has used antibiotics within the previous 2 months
  13. Has used prebiotics, probiotics, or drugs active on gastrointestinal motility, or a laxative of any class within 1 month
  14. Has used medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, hypoglycemic medications, and systemic corticosteroids within 2 weeks
  15. Female, who is pregnant, lactating or planning pregnancy during the study period
  16. Has participated in prebiotics or laxative trial within 3 months prior to enrollment or any other clinical trial within 1 month
  17. Donated blood within last 3 months
  18. Working overnight (e.g. 3rd shift)
  19. Excessive coffee and tea consumption (> 4 cups/day)
  20. Men and women who do excessive exercise regularly or athlete
  21. Men and women whom investigator is uncertain about subject's capability or willingness to comply with protocol requirement

Sites / Locations

  • Clinical Nutrition Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Raspberry and fructooligosaccharide

Raspberry

Arm Description

Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)

Red raspberries (1 cup equivalent)

Outcomes

Primary Outcome Measures

Changes in gut microbiome composition as measured by 16S rRNA gene sequencing in 12-week intervention of active treatment vs Experimental
gut microbiome composition changes

Secondary Outcome Measures

Changes in plasma red raspberry polyphenol metabolites in 12-week intervention of active treatment vs Experimental
Plasma red raspberry polyphenol metabolites
Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs Experimental
Plasma Insulin Sensitivity
Changes in plasma glucose response in 12-week intervention of active treatment vs Experimental
Plasma glucose response
Changes in plasma insulin response in 12-week intervention of active treatment vs Experimental
plasma insulin response
Changes in urine creatinine concentration in 12-week intervention of active treatment vs Experimental
urine creatinine concentration
Changes in urine red raspberry polyphenol metabolites in 12-week intervention of active treatment vs Experimental
urine red raspberry polyphenol metabolites
Changes in breath hydrogen exhalation in 12-week intervention of active treatment vs Experimental
breath hydrogen exhalation
Changes in Gastrointestinal Health as measured by Gastrointestinal Tract Questionnaire in 12-week intervention of active treatment vs Experimental
Gastrointestinal Health
Changes in blood pressure in 12-week intervention of active treatment vs Experimental
blood pressure

Full Information

First Posted
February 8, 2017
Last Updated
July 13, 2020
Sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
search

1. Study Identification

Unique Protocol Identification Number
NCT03049631
Brief Title
Red Raspberry Polyphenols on Gut Microbiome
Acronym
RRB2
Official Title
The Reciprocal Interactions Between Red Raspberry Polyphenols and Gut Microbiome Composition Affect Insulin Sensitivity
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
May 18, 2017 (Actual)
Primary Completion Date
July 6, 2020 (Actual)
Study Completion Date
July 6, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective aims are to assess the effects of regular consumption of red raspberries (RRB) with and without fructooligosaccharide (FOS) on the composition of the gut microbiota after 4 week intake and in parallel characterize plasma and urine metabolite profiles examining qualitative and quantitative intervention associated changes.
Detailed Description
The study will be performed as a single-blinded, randomized, crossover manner. Thirty subjects (20 insulin resistant subjects and 10 healthy subjects) will be randomly assigned into one of two sequences: sequence A (n=15) will be RRB then RRB+FOS (which means subject will consume only RRB (125 g/day(d) (equivalent to 1 cup fresh RRB)) with breakfast for 4 weeks, and then after a 4-week washout period, that subject will consume the RRB with FOS (125 g/d RRB and 8 g/d FOS) for 4 weeks); sequence B (n=15) will be RRB+FOS then RRB (which means subject will receive the RRB with FOS for 4 weeks, a 4-week washout, and then the RRB for another 4-week). At the beginning and end of each 4-week treatment, subjects will undergo a 6-h Study Day (4 study days in 12-week study duration) followed by a 1-h next morning follow-up visit. Subjects will be required to meet several inclusion and exclusion criteria, which will be assessed through online survey and on-site clinic assessments, including questionnaires, blood analysis and anthropometric measures. Eligible subjects will be invited to participate in the study. Each subject will be asked to come for 1 Screening Visit, 4 dinner pick-ups (the day before each Study Day), 4 Study Days and 6 Weekly Meetings. During the Screening Visit, subjects will read, sign and date a written Institutional Review Board approved Informed Consent Form prior to performing any study procedure. And then they will be assessed their qualification, instructed on the process for completing study questionnaires and counseled to restrict intake of colored plant foods rich in phytonutrients the 3 days prior to each Study Day. They will be asked to restrict alcohol intake, coffee/tea/ caffeinated beverage intake and moderate / vigorous physical activity and to drink plenty of water to maintain hydration in the 24 h prior to each Study Day. They will be instructed to come to the Clinical Nutrition Research Center (CNRC) the day before each Study Day to pick up their dinner meal and evening snack. Subjects will be asked to get at least 7 hours sleep and to come to the CNRC after a 10-h overnight fasting on each Study Day. Each Study Day will require subjects to be in the clinic for ~7 h to complete all baseline and post challenge beverage testing procedures, including a 6 h study day and a 1 h next morning follow-up visit. Subjects will be evaluated for compliance with the protocol (diet, exercise, sleep, fasting), have their body weight and blood pressure measured, ingest a cup of red raspberry drink (250 g RRB (equivalent to 2 cups fresh RRB) and 64 g glucose) and their blood, urine and feces samples will be collected.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Subjects, Pre-diabetes
Keywords
Pre-diabetes, red raspberry, fructooligosaccharide, metagenomics, polyphenol bioavailability, glycemic response, insulin response

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Raspberry and fructooligosaccharide
Arm Type
Active Comparator
Arm Description
Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
Arm Title
Raspberry
Arm Type
Experimental
Arm Description
Red raspberries (1 cup equivalent)
Intervention Type
Dietary Supplement
Intervention Name(s)
Raspberry and fructooligosaccharide
Intervention Description
Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
Intervention Type
Dietary Supplement
Intervention Name(s)
Raspberry
Intervention Description
Red raspberries (1 cup equivalent)
Primary Outcome Measure Information:
Title
Changes in gut microbiome composition as measured by 16S rRNA gene sequencing in 12-week intervention of active treatment vs Experimental
Description
gut microbiome composition changes
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Secondary Outcome Measure Information:
Title
Changes in plasma red raspberry polyphenol metabolites in 12-week intervention of active treatment vs Experimental
Description
Plasma red raspberry polyphenol metabolites
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs Experimental
Description
Plasma Insulin Sensitivity
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in plasma glucose response in 12-week intervention of active treatment vs Experimental
Description
Plasma glucose response
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in plasma insulin response in 12-week intervention of active treatment vs Experimental
Description
plasma insulin response
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in urine creatinine concentration in 12-week intervention of active treatment vs Experimental
Description
urine creatinine concentration
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in urine red raspberry polyphenol metabolites in 12-week intervention of active treatment vs Experimental
Description
urine red raspberry polyphenol metabolites
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in breath hydrogen exhalation in 12-week intervention of active treatment vs Experimental
Description
breath hydrogen exhalation
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in Gastrointestinal Health as measured by Gastrointestinal Tract Questionnaire in 12-week intervention of active treatment vs Experimental
Description
Gastrointestinal Health
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in blood pressure in 12-week intervention of active treatment vs Experimental
Description
blood pressure
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Other Pre-specified Outcome Measures:
Title
Changes in body weight in 12-week intervention of active treatment vs Experimental
Description
body weight
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in waist circumference in 12-week intervention of active treatment vs Experimental
Description
waist circumference
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in plasma triglycerides in 12-week intervention of active treatment vs Experimental
Description
plasma triglycerides
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in plasma LDL cholesterol in 12-week intervention of active treatment vs Experimental
Description
plasma LDL cholesterol
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks
Title
Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs Experimental
Description
plasma HDL cholesterol
Time Frame
baseline, 4 weeks, 8 weeks and 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Non-smoking1 man or woman, 20-60 years of age, inclusive Group 1 must have a fasting blood glucose between 100-125 mg/dL and inulin ≥ 8 μIU/mL Group 2 will have a fasting blood glucose below 100 mg/dL and the homeostasis model assessment method of insulin resistance (HOMA-IR) [glucose (μmol/L) × insulin (μunits/μL)/22.5] value less than 1 Judged to be in good health on the basis of the medical history Able to provide informed consent and comply with study procedures Able to comply to the study instructions (including dietary restrictions, consumption of study beverage, records of food diary and GI-tract questionnaire, sample collection procedure and study visit schedule) Able to maintain your usual physical activity pattern Able to abstain from alcohol consumption and avoid vigorous physical activity for 24 hours prior to and during study visit Exclusion Criteria: Systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg at screening visit. Major trauma or a surgical event within 2 months or longer depending on trauma or event and after consultation with PI. Weight change ≥4.5 kg (9.9 lbs) within 2 months Presence of chronic constipation, diarrhea or other chronic gastrointestinal complaint (e.g. irritable bowel syndrome) Had gastrointestinal barium opaque meal within 3 months History or presence of clinically important endocrine, cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, or biliary that, in the opinion of the investigator, could interfere with the interpretation of the study results History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer History of extreme dietary habits, as judged by the investigator (e.g., Atkins diet, etc.) History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional Vegan or other extreme dietary regimens as judged by the investigator. Has a known intolerance or sensitivity to any ingredients in the study products Has used antibiotics within the previous 2 months Has used prebiotics, probiotics, or drugs active on gastrointestinal motility, or a laxative of any class within 1 month Has used medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, hypoglycemic medications, and systemic corticosteroids within 2 weeks Female, who is pregnant, lactating or planning pregnancy during the study period Has participated in prebiotics or laxative trial within 3 months prior to enrollment or any other clinical trial within 1 month Donated blood within last 3 months Working overnight (e.g. 3rd shift) Excessive coffee and tea consumption (> 4 cups/day) Men and women who do excessive exercise regularly or athlete Men and women whom investigator is uncertain about subject's capability or willingness to comply with protocol requirement
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Britt M Burton-Freeman, Ph.D
Organizational Affiliation
Illinois Institute of Technology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Nutrition Research Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60616
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35421233
Citation
Zhang X, Zhao A, Sandhu AK, Edirisinghe I, Burton-Freeman BM. Red Raspberry and Fructo-Oligosaccharide Supplementation, Metabolic Biomarkers, and the Gut Microbiota in Adults with Prediabetes: A Randomized Crossover Clinical Trial. J Nutr. 2022 Jun 9;152(6):1438-1449. doi: 10.1093/jn/nxac037.
Results Reference
derived

Learn more about this trial

Red Raspberry Polyphenols on Gut Microbiome

We'll reach out to this number within 24 hrs